You are here: Industry Insights > GW Pharmaceuticals

News List

GW Pharma begins recruitment for US-based Sativex trial pharmatimes
November 06, 2020
GW Pharmaceuticals has initiated the first US phase III clinical trial studying nabiximols for multiple sclerosis (MS) associated spasticity.
Epidyolex (cannabidiol) reclassified as Schedule 5 in UK, relaxing control over drug europeanpharmaceuticalreview
June 28, 2020
GW Pharmaceuticals’s Epidyolex (cannabidiol) has been changed from a Schedule 2 drug to a Schedule 5 drug, making it exempt from virtually all controlled drug requirements.
After November rollout, GW Pharma says Epidiolex positioned for strong growth fiercepharma
March 06, 2019
GW Pharmaceuticals may be the first drugmaker to roll out a cannabis-based drug in the U.S., but it's unlikely to be the last—and that's why so many are keeping an eye on GW's Epidiolex launch.
GW Pharmaceuticals launches cannabis-based drug Epidiolex in US pharmaceutical-technology
November 06, 2018
UK-based GW Pharmaceuticals and its US division Greenwich Biosciences have launched an oral solution of cannabis-based drug Epidiolex in the US to treat seizures in Lennox-Gastaut syndrome (LGS) or Dravet syndrome patients aged two years and above.
GW Pharmaceuticals Appoints CFO, Adds UK Director contractpharma
March 08, 2017
Giacobello takes over as CFO; George transitions to managing director – UK